NASDAQ
22.77USD
+0.39 (+1.74%)
We have scored 11 news catalysts on Collegium Pharmaceutical, Inc. (COLL) over the past 12 months. The biggest single-day move next to one of them came Dec 30, 2025, when COLL closed −4.7%: “Collegium Announces the Closing of $980 Million Syndicated Credit Facility”. Coverage across the window leans positive (average ticker sentiment +0.75). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
738.5M
P/E
—
EPS
—
Beta
0.72
52W range
21.65-50.787
Day range
22.07–22.93
Open
22.25
Prev close
22.38
Volume
2M
Avg volume
603.1K
Dividend
0.00
IPO
2015-05-07
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Collegium Pharmaceutical, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for COLL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
